Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
DetailsGUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral® drugdelivery technologies to devel...
GUANGZHOU, China, September 8, 2021 (BUSINESSWIRE) --Bio-Thera Solutions, Ltd. (688177.SH) today announced that it has entered into a commercialization and license agreement with Sandoz to commercialize BAT1706, an anti- vascular endothelial growth factor (VEGF) monoclonal antibody that is a propose...
Guangzhou and London, 27 August 2021 – Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stel...
